Connecticut Wealth Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Connecticut Wealth Management’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-11,520	Closed	-$216K	–	332
2025 Q2	$216K	Hold	11,520	–	–	0.01%	297
2025 Q1	$207K	Hold	11,520	–	–	0.01%	293
2024 Q4	$194K	Hold	11,520	–	–	0.01%	264
2024 Q3	$186K	Hold	11,520	–	–	0.01%	320
2024 Q2	$94.7K	Hold	11,520	–	–	﹤0.01%	320
2024 Q1	$170K	Hold	11,520	–	–	0.01%	320
2023 Q4	$167K	Hold	11,520	–	–	0.01%	319
2023 Q3	$124K	Hold	11,520	–	–	0.01%	289
2023 Q2	$149K	Hold	11,520	–	–	0.01%	262
2023 Q1	$152K	Buy	11,520 +3,520	+44%	+$55.9K	0.01%	244
2022 Q4	$120K	Hold	8,000	–	–	0.01%	203
2022 Q3	$94K	Hold	8,000	–	–	0.01%	189
2022 Q2	$90K	Hold	8,000	–	–	0.01%	186
2022 Q1	$239K	Buy	+8,000	New	+$217K	0.02%	166

Other funds holding RIGL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CLGM

Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Connecticut Wealth Management's RIGL Position: Q3 2025 in Review

Connecticut Wealth Management sold out of Rigel Pharmaceuticals (RIGL) in Q3 2025, closing a stake of 11,520 shares — an estimated $216K sold.

Connecticut Wealth Management first reported a position in RIGL in Q1 2022 and held it in 14 quarters. The position peaked at $239K in Q1 2022. 169 funds tracked by Wall St. Rank hold RIGL as of Q3 2025.

Connecticut Wealth Management reported no remaining Rigel Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Connecticut Wealth Management sold 11,520 Rigel Pharmaceuticals shares in Q3 2025, an estimated $216K.
Connecticut Wealth Management first reported a position in Rigel Pharmaceuticals in Q1 2022 and held it in 14 quarters.
Connecticut Wealth Management's Rigel Pharmaceuticals position peaked at $239K in Q1 2022.
169 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2025.

Based on Connecticut Wealth Management's 13F filing for Q3 2025, filed 13 Nov 2025.